162 related articles for article (PubMed ID: 35198796)
1. Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial.
Micallef S; Sostelly A; Zhu J; Baverel PG; Mercier F
Contemp Clin Trials Commun; 2022 Apr; 26():100901. PubMed ID: 35198796
[TBL] [Abstract][Full Text] [Related]
2. Optimization of EWOC principle in BLRM design for phase 1 oncology trials.
Guo X; Kent S; Maity A; Zhong W
J Biopharm Stat; 2024 Apr; ():1-17. PubMed ID: 38562014
[TBL] [Abstract][Full Text] [Related]
3. Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
Ananthakrishnan R; Green S; Chang M; Doros G; Massaro J; LaValley M
Contemp Clin Trials Commun; 2017 Mar; 5():34-48. PubMed ID: 29740620
[TBL] [Abstract][Full Text] [Related]
4. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
5. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
[TBL] [Abstract][Full Text] [Related]
6. Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method.
Ji L; Lewinger JP; Krailo M; Groshen S; Conti DV; Asgharzadeh S; Sposto R
Pharm Stat; 2019 Nov; 18(6):659-670. PubMed ID: 31237419
[TBL] [Abstract][Full Text] [Related]
7. GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials.
Dinart D; Fraisse J; Tosi D; Mauguen A; Touraine C; Gourgou S; Le Deley MC; Bellera C; Mollevi C
BMC Med Inform Decis Mak; 2020 Jun; 20(1):134. PubMed ID: 32580715
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
Chen Z; Tighiouart M; Kowalski J
Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
[TBL] [Abstract][Full Text] [Related]
9. Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.
Zhang Y; Kutner M; Chen Z
Biom J; 2021 Oct; 63(7):1476-1492. PubMed ID: 33969525
[TBL] [Abstract][Full Text] [Related]
10. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.
Zhou H; Yuan Y; Nie L
Clin Cancer Res; 2018 Sep; 24(18):4357-4364. PubMed ID: 29661774
[TBL] [Abstract][Full Text] [Related]
11. Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.
Wheeler GM; Sweeting MJ; Mander AP
Stat Med; 2017 Jul; 36(16):2499-2513. PubMed ID: 28295513
[TBL] [Abstract][Full Text] [Related]
12. A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades.
Diniz MA; Kim S; Tighiouart M
Stats (Basel); 2020 Sep; 3(3):221-238. PubMed ID: 33073179
[TBL] [Abstract][Full Text] [Related]
13. Incoherent dose-escalation in phase I trials using the escalation with overdose control approach.
Wheeler GM
Stat Pap (Berl); 2018 Jun; 59(2):801-811. PubMed ID: 29875549
[TBL] [Abstract][Full Text] [Related]
14. Escalation with overdose control for phase I drug-combination trials.
Shi Y; Yin G
Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
[TBL] [Abstract][Full Text] [Related]
15. Escalation with overdose control using time to toxicity for cancer phase I clinical trials.
Tighiouart M; Liu Y; Rogatko A
PLoS One; 2014; 9(3):e93070. PubMed ID: 24663812
[TBL] [Abstract][Full Text] [Related]
16. Dose-finding approach for dose escalation with overdose control considering incomplete observations.
Mauguen A; Le Deley MC; Zohar S
Stat Med; 2011 Jun; 30(13):1584-94. PubMed ID: 21351289
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
Tighiouart M; Cook-Wiens G; Rogatko A
J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
[TBL] [Abstract][Full Text] [Related]
18. Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding.
Rogatko A; Cook-Wiens G; Tighiouart M; Piantadosi S
Entropy (Basel); 2015 Aug; 17(8):5288-5303. PubMed ID: 27156869
[TBL] [Abstract][Full Text] [Related]
19. Bayesian dose escalation with overdose and underdose control utilizing all toxicities in Phase I/II clinical trials.
Tu J; Chen Z
Biom J; 2024 Jan; 66(1):e2200189. PubMed ID: 38047521
[TBL] [Abstract][Full Text] [Related]
20. An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information.
Yang C; Li Y
Stat Med; 2024 Feb; 43(4):689-705. PubMed ID: 38110304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
